Patents by Inventor Denise Bartels-Morozov

Denise Bartels-Morozov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST CANINE PD-1
    Publication number: 20240084004
    Abstract: The present invention discloses antibodies to canine PD-I that have specific sequences and a high binding affinity for canine PD-I. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: May 8, 2023
    Publication date: March 14, 2024
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Antibodies against canine PD-1
    Patent number: 11680097
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: June 20, 2023
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • PD-L1 ANTIBODIES BINDING CANINE PD-L1
    Publication number: 20220389114
    Abstract: The present invention discloses antibodies including caninized antibodies against canine PD-L1 with specific properties. The present invention further relates to epitopes of canine PD-L1 that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes. The invention further discloses the use of the caninized anti-canine PD-LI antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: August 15, 2022
    Publication date: December 8, 2022
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • PD-L1 antibodies binding canine PD-L1
    Patent number: 11447561
    Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: September 20, 2022
    Assignee: Intervet, Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Caninized murine antibodies to human PD-1
    Patent number: 10927172
    Abstract: The present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: February 23, 2021
    Assignee: INTERVET INC.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey, Leonard Presta
  • ANTIBODIES AGAINST CANINE PD-1
    Publication number: 20200354450
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: June 5, 2020
    Publication date: November 12, 2020
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Antibodies against canine PD-1
    Patent number: 10711061
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: July 14, 2020
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • PD-L1 ANTIBODIES BINDING CANINE PD-L1
    Publication number: 20200109212
    Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
    Type: Application
    Filed: December 18, 2019
    Publication date: April 9, 2020
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • PD-L1 antibodies binding canine PD-L1
    Patent number: 10550194
    Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L1 that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: February 4, 2020
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • CANINIZED MURINE ANTIBODIES TO HUMAN PD-1
    Publication number: 20180346570
    Abstract: The present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.
    Type: Application
    Filed: June 13, 2018
    Publication date: December 6, 2018
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey, Leonard Presta
  • ANTIBODIES AGAINST CANINE PD-1
    Publication number: 20180251554
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: February 12, 2018
    Publication date: September 6, 2018
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • PD-L1 ANTIBODIES BINDING CANINE PD-L1
    Publication number: 20180237535
    Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L1 that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
    Type: Application
    Filed: September 29, 2015
    Publication date: August 23, 2018
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Caninized murine antibodies to human PD-1
    Patent number: 10023636
    Abstract: The present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: July 17, 2018
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey, Leonard G. Presta
  • Antibodies against canine PD-1
    Patent number: 9944704
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: April 17, 2018
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • ANTIBODIES AGAINST CANINE PD-1
    Publication number: 20160333096
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 17, 2016
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • CANINIZED MURINE ANTIBODIES TO HUMAN PD-1
    Publication number: 20160319018
    Abstract: The present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 3, 2016
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey, Leonard G. Presta